Cargando…

Nothing but NET: A review of norepinephrine transporter expression and efficacy of (131)I-mIBG therapy

Neuroblastoma is unique amongst common pediatric cancers for its expression of the norepinephrine transporter (NET), enabling tumor-selective imaging and therapy with radioactive analogues of norepinephrine. The majority of neuroblastoma tumors are avid for (123)I-metaiodobenzaguanidine (mIBG) on im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Streby, Keri A, Shah, Nilay, Ranalli, Mark A, Kunkler, Anne, Cripe, Timothy P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237663/ https://www.ncbi.nlm.nih.gov/pubmed/25175627 http://dx.doi.org/10.1002/pbc.25200

Ejemplares similares

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma
por: Riaz, Saima, et al.
Publicado: (2018)

Cardiac (123)I-mIBG Imaging in Heart Failure
por: Verschure, Derk O., et al.
Publicado: (2022)

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for (131)I mIBG treatment of neuroendocrine tumours
por: Gear, Jonathan, et al.
Publicado: (2020)

Improved outcome of (131)I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma
por: Corroyer-Dulmont, Aurélien, et al.
Publicado: (2017)

A European myocardial (123)I-mIBG cross-calibration phantom study
por: Verschure, Derk O., et al.
Publicado: (2017)

Analysis of quantitative [I-123] mIBG SPECT/CT in a phantom and in patients with neuroblastoma
por: Brady, Samuel L., et al.
Publicado: (2019)

Misdiagnosis of Paraganglioma by (123)I-mIBG Without Stable Iodine Blockade of Thyroidal Radioiodine Uptake
por: Chen Cardenas, Stanley M, et al.
Publicado: (2020)

Comparison Between Diffusion‐Weighted MRI and (123)I‐mIBG Uptake in Primary High‐Risk Neuroblastoma
por: Privitera, Laura, et al.
Publicado: (2020)

Can early phase cardiac [(123)I]mIBG images be used to diagnose Lewy body disease?
por: Roberts, Gemma, et al.
Publicado: (2022)

(123)I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel
por: Lewington, V., et al.
Publicado: (2016)

The relation between cardiac (123)I-mIBG scintigraphy and functional response 1 year after CRT implantation
por: Verschure, D O, et al.
Publicado: (2020)

The prognostic value of (123)I-mIBG SPECT cardiac imaging in heart failure patients: a systematic review
por: Pontico, Mariano, et al.
Publicado: (2021)

Comparison of Taiwanese and European Calibration Factors for Heart-to-Mediastinum Ratio in Multicenter (123)I-mIBG Phantom Studies
por: Okuda, Koichi, et al.
Publicado: (2023)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy
por: Sze, W C C, et al.
Publicado: (2013)

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.
por: Jodrell, D. I., et al.
Publicado: (1988)

Role of cardiac (123)I-mIBG imaging in predicting arrhythmic events in stable chronic heart failure patients with an ICD
por: De Vincentis, Giuseppe, et al.
Publicado: (2018)

Cardiac sympathetic activity in chronic heart failure: cardiac (123)I-mIBG scintigraphy to improve patient selection for ICD implantation
por: Verschure, D. O., et al.
Publicado: (2016)

Using systematic reviews to identify research gaps - a case study: mIBG for the treatment of neuroblastoma in children
por: Wilson, Jayne, et al.
Publicado: (2013)

The Vital Role of (131) I-MIBG in Localization of Paraganglioma at Unusual Sites
por: Singhal, Tejasvini, et al.
Publicado: (2022)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

Myocardial (123)I-mIBG scintigraphy in relation to markers of inflammation and long-term clinical outcome in patients with stable chronic heart failure
por: Verschure, Derk O., et al.
Publicado: (2016)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors
por: Grand-Guillaume, Joana, et al.
Publicado: (2023)

Polymorphism of SLC6A2 gene does not influence outcome of myocardial (123)I-mIBG scintigraphy in patients with chronic heart failure
por: Verschure, Derk O., et al.
Publicado: (2016)

Objective comparison of lesion detectability in low and medium-energy collimator iodine-123 mIBG images using a channelized Hotelling observer
por: Gregory, Rebecca A, et al.
Publicado: (2017)

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
por: DuBois, S G, et al.
Publicado: (2015)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience
por: Verma, Priyanka, et al.
Publicado: (2012)

Cardiac Sympathetic Activity and Rhythm Control Following Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation—A Prospective (123)I-mIBG-SPECT/CT Imaging Study
por: Lange, Philipp S., et al.
Publicado: (2021)

Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
por: Ezziddin, Samer, et al.
Publicado: (2012)

Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2013)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Metastatic Pheochromocytoma Diagnosed with (131) I-MIBG SPECT/CT Imaging in a Patient with Pathogenic VHL Mutation
por: Vankadari, Kousik, et al.
Publicado: (2022)

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy
por: Mastrangelo, S, et al.
Publicado: (2001)

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors
por: Bushnell, David L, et al.
Publicado: (2014)

Unusual Presentation of Bladder Paraganglioma: Comparison of (131)I MIBG SPECT/CT and (68)Ga DOTANOC PET/CT
por: Jain, Tarun Kumar, et al.
Publicado: (2016)

(68)Ga-DOTATATE PET/CT Compared with (131)I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors
por: Shahrokhi, Pezhman, et al.
Publicado: (2020)

MON-202 Germline SDHB Exon 1 Deletion Is Associated with Absence of (131)I-metaiodobenzylguanidine (MIBG) Uptake in Malignant Paragangliomas
por: Petenuci, Janaina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h8ajj2ul4m1t8hhe3e27hndhdb